Clinical Research Informer

Enhertu gets breakthrough tag in HER2-low breast cancer

pharmaphorum

APRIL 27, 2022

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic breast cancer. The post Enhertu gets breakthrough tag in HER2-low breast cancer appeared first on.

Sales

Sales Drugs Antibody Licensing

Pfizer and Arvinas win UK’s fast track tag for breast cancer drug

Pharmaceutical Technology

AUGUST 1, 2023

Vepdegestrant was awarded the Innovation Passport designation for treating advanced or metastatic breast cancer.

Drugs

Gilead tags Merck for first-line triple negative breast cancer trial

pharmaphorum

OCTOBER 29, 2021

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get? “This helps further our ambition of displacing chemotherapy with Trodelvy to improve outcomes for people living with cancer,” said Gilead’s chief medical officer Merdad Parsey.

Trials

Trials Sales FDA Approval Production

AROMATASE INHIBITORS IN BREAST CANCER

Pharma Tutor

DECEMBER 27, 2021

AROMATASE INHIBITORS IN BREAST CANCER. Read more about AROMATASE INHIBITORS IN BREAST CANCER Log in or register to post comments Read more about AROMATASE INHIBITORS IN BREAST CANCER Log in or register to post comments About Authors. MANISHA KOTADIYA*, JAYDEEP SAVALIYA. DOWNLOAD AS PDF.

Pharmacy

First patient dosed with PI3K? inhibitor for solid tumours

Drug Discovery World

APRIL 17, 2023

Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The study will be conducted in two parts.

Clinical Trials

Clinical Trials Clinical Trials Trials Medicine

Epigenetics discovery could lead to new class of cancer drugs

Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome.

Gene Expression

Gene Expression Gene DNA RNA

Blue Note leukaemia DTx gets FDA breakthrough tag

pharmaphorum

JANUARY 11, 2022

It has since been joined by other products in the software as a medical device (SaaMD) category, including Pear Therapeutics’ alcohol-use disorder candidate Pear-009 and another Blue Note DTx, codenamed BNT001, which is also being tested for anxiety and depression in cancer patients.

Development

Development Production Drugs

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

pharmaphorum

DECEMBER 23, 2021

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The post FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag appeared first on. Daiichi Sankyo and AZ are close collaborators in the ADC arena.

Drugs

Drugs Antibody Clinical Trials Clinical Trials

You can’t afford to get cancer

World of DTC Marketing

DECEMBER 13, 2021

OPENING: American cancer patients spent more than $21 billion on their care in 2019. As cancer survival rates rise, so do the price tags of life-saving treatments. Some cancer patients may face out-of-pocket costs of nearly $12,000 a year for one drug. What makes cancer such a financial killer? ScienceNews.com.

Drugs

Drugs FDA Approval Medicine Containment

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Delveinsight

FEBRUARY 25, 2021

GRAIL and Quest collaborate for the cancer blood test. Cancer detection company GRAIL has announced a collaboration with Quest Diagnostics that sees Quest proffering phlebotomy services to bolster GRAIL’s multi-cancer early detection blood test Galleri. Brain organoids grown in the lab mimic infant’s brains.

DNA

DNA In-Vivo Genetics Medicine

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

AUGUST 17, 2020

To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Cell-Based Immunotherapy vs. Immune Biologics. asks Dr. Suri.

Protein

Protein Engineer Immune Response In-Vivo

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

MAY 4, 2021

up 28%, primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications, as well as the metastatic castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019; and. View source version on businesswire.com : [link]. Source: Pfizer Inc.

Vaccination

Vaccination Vaccine Production Sales

Clinical Research Informer

Enhertu gets breakthrough tag in HER2-low breast cancer

Pfizer and Arvinas win UK’s fast track tag for breast cancer drug

Trending Sources

Gilead tags Merck for first-line triple negative breast cancer trial

AROMATASE INHIBITORS IN BREAST CANCER

First patient dosed with PI3K? inhibitor for solid tumours

Epigenetics discovery could lead to new class of cancer drugs

Blue Note leukaemia DTx gets FDA breakthrough tag

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

You can’t afford to get cancer

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

Stay Connected